STOCK TITAN
  1. Home
  2. News
  3. CTXR

Citius Pharmaceuticals Inc - CTXR STOCK NEWS

Welcome to our dedicated news page for Citius Pharmaceuticals (Ticker: CTXR), a resource for investors and traders seeking the latest updates and insights on Citius Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Citius Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Citius Pharmaceuticals's position in the market.

News
Citius Pharmaceuticals Announces $15 Million Registered Direct Offering
Rhea-AI Summary
Citius Pharmaceuticals Inc. announces a $15 million registered direct offering of common stock and warrants. The offering includes 21,428,574 shares at $0.70 per share with accompanying warrants to purchase additional shares at $0.75 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
offering
-
News
Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma
Rhea-AI Summary
Citius Pharmaceuticals, Inc. (CTXR) collaborates with the University of Minnesota Masonic Cancer Center and City of Hope to expand Phase 1 trial of LYMPHIR plus CAR-T therapy for B-cell lymphomas. The study aims to determine the maximum tolerated dose and evaluate the potential benefits of LYMPHIR in combination with CAR-T treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2%
Tags
clinical trial
-
News
Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference
Rhea-AI Summary
Citius Pharmaceuticals, Inc. announced that Chairman and CEO Leonard Mazur will present at the 14th Annual LD Micro Invitational investor conference in New York City on April 9, 2024. The presentation will be both in-person and virtual, starting at 3:30pm ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.73%
Tags
conferences
News
Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
Rhea-AI Summary
Citius Pharmaceuticals, Inc. receives FDA acceptance for the resubmission of the Biologics License Application (BLA) for LYMPHIR™, with a PDUFA target action date set for August 13, 2024. The company aims to develop an IL-2-based immunotherapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) patients, addressing a critical unmet medical need.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.2%
Tags
clinical trial
-
News
Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program
Rhea-AI Summary
Citius Pharmaceuticals, Inc. (CTXR) secures $2.4 million in non-dilutive capital through New Jersey's NOL Program. The funding will support the advancement of their critical care product pipeline.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.34%
Tags
none
-
News
Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf Registration
Rhea-AI Summary
Citius Pharmaceuticals, Inc. (CTXR) files Form S-3 shelf registration to replace expiring statement, aiming for continued development and commercialization of critical care products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.5%
Tags
none
News
Citius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor Conferences
Rhea-AI Summary
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) announces participation in two investor conferences with Chairman and CEO Leonard Mazur presenting at BIO CEO and Investor Conference and Sidoti Small-Cap Virtual Conference. Details of the presentations and registration information provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.8%
Tags
conferences
-
News
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update
Rhea-AI Summary
Citius Pharmaceuticals, Inc. resubmitted LYMPHIR™ BLA to the FDA and completed Mino-Lok® Phase 3 trial enrollment. Financially, they reported $20.3 million in cash, with R&D expenses at $2.6 million and a net loss of $9.2 million for Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.07%
Tags
earnings
-
News
Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
Rhea-AI Summary
Citius Pharmaceuticals, Inc. announces the resubmission of the BLA for LYMPHIR™ to the FDA for the treatment of CTCL, expecting FDA acceptance within 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.53%
Tags
none
News
Citius Pharmaceuticals Announces Nomination of Pharmaceutical Executive Robert J. Smith to its Board of Directors
Rhea-AI Summary
Citius Pharmaceuticals, Inc. announces the nomination of Robert J. Smith as an Independent Director to its Board of Directors, subject to shareholder approval at the Annual Shareholders' Meeting in March 2024. Mr. Smith, a seasoned pharmaceutical executive, has extensive experience with leading pharmaceutical companies, and his appointment is expected to bring valuable insights to Citius.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.71%
Tags
management
Stock CTXR logo
Citius Pharmaceuticals Inc

Nasdaq:CTXR

CTXR Rankings

#4224 Ranked by Market Cap
#3945 Ranked by Stock Gains
N/A Ranked by Dividends

CTXR Stock Data

125.34M
146.77M
7.74%
17.01%
7.81%
Medicinal and Botanical Manufacturing
Manufacturing
Link
US
Cranford

About CTXR

citius pharmaceuticals, inc., a specialty pharmaceutical company, develops and commercializes critical care products. it primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. the company is developing mino-lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in phase iii clinical trials; mino-wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; halo-lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and novecite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. citius pharmaceuticals, inc. was founded in 2007 and is headquartered in cranford, new jersey.